Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Cash from Investing Activities (2020 - 2023)

Historic Cash from Investing Activities for Journey Medical (DERM) over the last 4 years, with Q1 2023 value amounting to -$5.0 million.

  • Journey Medical's Cash from Investing Activities rose 7500.0% to -$5.0 million in Q1 2023 from the same period last year, while for Dec 2023 it was -$5.0 million, marking a year-over-year increase of 7500.0%. This contributed to the annual value of -$15.0 million for FY2024, which is 20000.0% down from last year.
  • Latest data reveals that Journey Medical reported Cash from Investing Activities of -$5.0 million as of Q1 2023, which was up 7500.0% from -$20.0 million recorded in Q1 2022.
  • Over the past 5 years, Journey Medical's Cash from Investing Activities peaked at -$200000.0 during Q4 2020, and registered a low of -$20.0 million during Q1 2022.
  • For the 4-year period, Journey Medical's Cash from Investing Activities averaged around -$6.6 million, with its median value being -$3.1 million (2021).
  • In the last 5 years, Journey Medical's Cash from Investing Activities tumbled by 50000.0% in 2021 and then soared by 7500.0% in 2023.
  • Journey Medical's Cash from Investing Activities (Quarter) stood at -$200000.0 in 2020, then crashed by 500.0% to -$1.2 million in 2021, then plummeted by 1566.67% to -$20.0 million in 2022, then soared by 75.0% to -$5.0 million in 2023.
  • Its last three reported values are -$5.0 million in Q1 2023, -$20.0 million for Q1 2022, and -$1.2 million during Q4 2021.